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Hypo-responsiveness to controlled ovarian stimulation is an undervalued topic in
reproductive medicine. This phenomenon manifests as a low follicles output rate (FORT)
with a discrepancy between the relatively low number of pre-ovulatory follicles which
develop following ovarian stimulation as compared to the number of antral follicles
available at the start of stimulation. The pathophysiology mechanisms explaining the
ovarian resistance to gonadotropin stimulation are not fully understood, but the fact that
both hypo-responders and normal responders share similar phenotypic characteristics
suggests a genotype-based mechanism. Indeed, existing evidence supports the
association between specific gonadotropin and their receptor polymorphisms and
ovarian hypo-response. Apart from genotypic trait, environmental contaminants and
oxidative stress might also be involved in the hypo-response pathogenesis. The ratio
between the number of oocytes collected at the ovum pick up and the number of
antral follicles at the beginning of OS [Follicle to oocyte index (FOI)] is proposed as a
novel parameter to assess the hypo-response. Compared with traditional ovarian reserve
markers, FOI might reflect most optimally the dynamic nature of follicular growth in
response to exogenous gonadotropin. In this review, we contextualize the role of FOI
as a parameter to identify this condition, discuss the underlying mechanisms potentially
implicated in the pathogenesis of hypo-response, and appraise possible the treatment
strategies to overcome hyper-responsiveness to gonadotropin stimulation.
Keywords: hypo-response, ovarian stimulation, ovulation induction, assisted reproductive technology, in vitro
fertilization, follicle to oocyte index, follicle output rate, POSEIDON criteria
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INTRODUCTION
Ovarian stimulation (OS) is an essential step in assisted
reproductive technology (ART). The conventional OS
approaches lead to sufficient follicular growth and proper
estrogen levels in the majority of women. In this regard, the
number of mature oocytes retrieved is the parameter most often
used to assess ovarian response to exogenous gonadotropin, as
oocyte number is closely related to the likelihood of achieving a
live birth in ART (1). Based on oocyte number, women are usually
classified as poor, suboptimal, normal or hyper-responders (2, 3).
Outside these categories, a subgroup of women with impaired
response to gonadotropin, termed “hypo-responders,” also exists.
An unexpected ovarian resistance to OS with use of standard
age- and BMI-matched doses of exogenous FSH characterizes
these patients (4–6). The clinical manifestation of ovarian
resistance includes either an “initial slow response” to FSH
stimulation concerning estradiol levels rise and follicle growth
(7, 8) or can be retrospectively diagnosed in women who require
higher-than-expected doses of gonadotropins considering their
age, BMI, and ovarian reserve (9). In contrast to “suboptimal
response,” which is based essentially on the number of oocytes
retrieved (between 4 and 9) (10), the hypo-response profile
refers to those patients who show a resistance to gonadotropin
stimulation and in which the number of oocytes retrieved at the
end of stimulation is not consistent with the number of antral
follicle count (AFC) available at the beginning of OS. In this
review, we (1) illustrate how to identify patients with ovarian
resistance to exogenous gonadotropins who undergo ART by
use of a new marker named follicle-to-oocyte index (FOI), (2)
discuss the underlying pathogenetic mechanisms associated
with hypo-response, and lastly, (3) critically appraise possible
treatment strategies to overcome this condition.
ASSESSMENT OF HYPO-RESPONSE
The prediction of ovarian response is crucial for an optimal
and individualized management in the context of OS. It
also allows clinicians to better counsel women about the
risk of adverse events following OS, such as protracted
cycles, cycle cancellation due to poor ovarian response, or
ovarian hyperstimulation syndrome (OHSS). Generally, the
ovarian response to gonadotropin stimulation can be explained
by the interplay between demographic and anthropometric
characteristics, and the individual’s ovarian reserve. In this
regard, biological (AFC) and biochemical [Anti-Müllerian
hormone (AMH)] markers have been introduced to predict both
the poor and hyper response with fairly good accuracy (3).
In our opinion, these biomarkers represent a “static” snapshot
of the individual ovarian reserve which do not properly reflect the
“dynamic” nature of follicular growth in response to exogenous
OS. An interesting model to assess hypo-responsiveness during
OS is the follicle output rate (FORT) introduced by Genro et al.
in 2011 (11). This index is calculated as the ratio between the
number of pre-ovulatory follicles obtained in response to OS
with FSH administration and the pre-existing pool of small
antral follicles (11, 12). A low FORT (e.g., 30%) indicates
hypo-response, due to the discrepancy between the relatively low
number of pre-ovulatory follicles which develop following OS as
compared to the number of antral follicles available at the start
of stimulation (Figure 1). Notably, low FORT indices are not
associated with reduced ovarian markers, thereby suggesting that
patients undergoing OS can present with a low FORT despite the
presence of adequate ovarian markers (11).
Another parameter that might be used to assess hypo-
responsiveness is the ovarian sensitivity index (OSI) (13). OSI is
calculated by dividing the total administered FSH dose and the
number of retrieved oocytes. A high OSI index reflects ovarian
resistance to OS thereby suggesting a hypo-response profile.
Although both methods seem to be useful in the evaluation
of hypo-response, some drawbacks should be considered. The
FORT does not assess the actual number of oocytes retrieved,
which is the parameter more strictly associated with live birth
rates (1). On the other hand, OSI does not take into account
the type of gonadotropin adopted (recombinant or urinary) nor
does it consider the gonadotropin regimen utilized. In fact, recent
evidence indicates that the use of luteinizing hormone (LH)
or LH-like activity during OS improves follicle development in
specific subgroups of women, including hypo-responders (14,
15). Along the same lines, OSI indices might be misleading if
inappropriate low starting doses of exogenous gonadotrophins
are given. Lastly, it has been suggested that OSI results are
associated with AMH levels in women undergoing IVF (13), thus
making it a less robust index to assess the dynamical aspect of the
follicular response to OS.
FOLLICLE-TO-OOCYTE INDEX (FOI)
We propose an alternative approach to address the ovarian
resistance to gonadotropin stimulation (or hypo-responsiveness)
based on the concept of FORT, namely, the ratio between the total
number of oocytes collected at the end of OS, and the number
of antral follicles available at the start of stimulation (Follicle-
to-Oocyte Index [FOI]) (Figures 2, 3). Figure 2 illustrates
the difference between hypo-response to OS and suboptimal
FIGURE 1 | Ovarian sensitivity using FORT [adapted from (12)].
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FIGURE 2 | Ovarian sensitivity using the Follicle-to-Oocyte Index (FOI). Case number 1 depicts a patient with normal FOI, in whom the number of oocytes retrieved
was consistent with the AFC at the start of stimulation. Case number 2 illustrates a patient with suboptimal number of oocytes retrieved (between 4 and 9), but with a
normal Follicle-to-Oocyte index (FOI >50%). Case number 3 shows a patient with both hypo-response and suboptimal oocyte number. This patient had only 7
oocytes collected despite an AFC of 15 at the beginning of stimulation (FOI ≤ 50%). Case number 4 depicts a patient with both hypo-response and poor response.
FIGURE 3 | Possible causes of low Follicle-to-Oocyte Indeces.
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response. In detail, both cases 2 and 3 show a suboptimal
response with the number of oocytes retrieved between 4 and
9. However, only case 3 illustrates a hypo-response profile in
which just 7 oocytes were collected despite an AFC of 15 at the
beginning of stimulation (FOI < 50%). On the other hand, in
case 2, despite the low oocyte number, this hypothetical woman
had 5 oocytes retrieved from an AFC of 7, thus illustrating
a normal follicle-to-oocyte index (FOI >50%). Lastly, case
number 4 depicts a patient with both hypo-response and poor
response. Based on the examples above it is therefore clear
that hypo-responsiveness and suboptimal/poor response are not
synonymous.
FOI may be used alone or combined with FORT to most
optimally reflect the ovarian resistance to OS. The results of FOI
can also help to understand whether it is possible to exploit
the ovarian reserve further using pharmacologic interventions.
Lastly, FOI could be useful to predict the likelihood of success
in ART, both concerning the chances of achieving at least one
euploid blastocyst for transfer in each patient–the so-called
POSEIDON marker of successful outcome-, (4, 6) as well as
pregnancy success. Thus, low FOI values imply that only a
fraction of available antral follicles was exploited during OS,
suggesting that there might be therapeutic opportunities to
change the fate of these women in a subsequent OS. Naturally,
technical aspects related to oocyte retrieval and triggering for
final oocyte maturation, both of which can influence FOI results,
should be taken into account in patients with low FOI. The
FOI is under evaluation by an ongoing multicenter Italian study
(Impact ofGonadotropinGENetics Profile andOvArian Reserve
on Controlled Ovarian Stimulation, the GENACOS study). In
future, we envision refining FOI by including the amount of
gonadotropin used during OS. Additionally, a prediction model
can be developed to estimate the likely number of oocytes to
be retrieved at the end of OS by computing the results of AFC,
polymorphisms of gonadotrophins and their receptors, and FSH
starting dose.
PATHOGENESIS OF HYPO-RESPONSE
The pathophysiology mechanisms explaining hypo-
responsiveness to OS are not fully understood. However,
the link between ovarian response and individual genotype has
been postulated by several authors (16–22). Furthermore, the
fact that both hypo-responders and normal responders share
similar phenotypic characteristics suggests a genotype-based
mechanism (23–27). In other words, hypo-responders might
have a particular genotype profile which influences their response
to OS (28). Indeed, several studies support this concept. In a 2013
sizeable longitudinal study, we found that a common LH beta
subunit variant was associated with increased FSH consumption
during OS (29). In another study, we found that the prevalence
of hypo-response was higher in G allele carriers of a common
FSH receptor (FSHR) polymorphism (p.N680SA > G, rs6166)
than in wild-type haplotypes (30). Furthermore, in vitro studies
using human granulosa cells demonstrated that p.N680SA>G
G homozygous showed higher resistance to FSH stimulation
than p.N680SA>G A homozygous carriers at the FSH receptor
level (31, 32). Along the same lines, it has been shown that
N680SA>G G homozygous display increased basal endogenous
FSH levels (33) compared to p.N680SA>G A homozygous, thus
corroborating the hypothesis of an impaired FSHR function in
carries of G allele. Added to this, in vivo studies have shown that
carriers of another FSHR polymorphism, namely, A allele, have
ovarian resistance to OS as expressed by a higher consumption
of exogenous gonadotropin than G allele carriers (34, 35). It is
out of the scope of our paper to provide readers a comprehensive
review of the impact of gonadotropin receptors polymorphisms
in OS, but a recently published systematic review and meta-
analysis by our group confirmed that polymorphism of FSHR
could impair ovarian response to exogenous gonadotropin
(28).
Apart from the genotypic trait, there is also evidence that
environmental contaminants might influence ovarian response
to gonadotropin stimulation. In a 2014 retrospective study,
we showed that elevated intra-follicular levels of benzene were
associated with a reduced number of oocytes retrieved and
embryos available for transfer in women who underwent IVF
(36) (Figure 4). The mechanism underlying this phenomenon
is not clear, but the authors hypothesized that the toxic effect
of benzene leads to a transduction deficiency of the FSHR. In
fact, this hypothesis is supported by the fact that basal FSH
levels were significantly higher in women with higher intra-
follicular benzene levels than in women with low intra-follicular
benzene levels (36). Other pollutants were also associated with an
impaired ovarian response in IVF (37). In a 2017 retrospective
study, a significant inverse association was found between the
levels of polychlorinated biphenyl congeners (PBC) in follicular
fluid of women undergoing ART and the ovarian response to
gonadotropins measured by both the number of oocyte retrieved
and estradiol levels (38). Notably, the number of antral follicles
also seem to be affected by the levels of PCB congeners in
follicular fluid (38).
Lastly, accumulating evidence indicates that oxidative stress
might also affect both folliculogenesis and spermatogenesis
(39, 40). In detail, it was hypothesized that oxidative stress
FIGURE 4 | Number of oocytes collected form patients with low (Group A) vs.
high intrafollicular benzene levels [adapted from (36)]. *stand for statistically
significant.
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and excessive free radicals such as reactive oxygen species
(ROS) might influence the quality of oocytes, spermatozoa, and
embryos, as well as their environments (41), thus negatively
affecting the outcome of IVF (39, 42). In a 2016 pilot study
involving women with polycystic ovarian syndrome (PCOS)
(43), in whom oxidative stress seemed to be a relevant
pathogenetic factor, we demonstrated that myo-inositol plus
active antioxidants (glutathione, selenium, vitamins C and E,
and zinc), given twice a day for 5 months preceding OS, had a
favorable effect on the outcome of IVF by increasing the number
of mature oocytes (44). Recently, in 2018, Xu et al. reported the
results of a randomized controlled trial with the use of coenzyme
Q10 as a pretreatment to OS in patients with low prognosis
in ART (45). The authors utilized the POSEIDON criteria to
enroll young patients (<35 years-old; POSEIDON group 3) with
poor ovarian reserve parameters (4, 6). In their study, the use
of coenzyme Q10 (200mg thrice daily for 60 days preceding the
IVF cycle) was associated with an increased number of retrieved
oocytes, fertilization rate, and high-quality embryos than in non-
treated women. Lastly, a 2017 Cochrane meta-analysis supports
the above observations by showing that antioxidant intake might
provide a benefit for subfertile women who undergo ART (42).
Whether oxidative stress has a role in the pathogenesis of hypo-
response deserves further investigation.
CLINICAL MANAGEMENT OF PATIENTS
WITH HYPO-RESPONSIVENESS TO
OVARIAN STIMULATION
In clinical practice, ovarian resistance to gonadotropin
stimulation is still a largely undervalued issue. Overall, clinicians
do not ask themselves whether or not the number of oocytes
retrieved after OS was consistent with the patient’s potential
based on the results of AFC at the start of stimulation. In our
opinion, the number of oocytes retrieved should be interpreted
in the light of an individual ovarian reserve. For example, in a
woman with an AFC of 12, recruitment of 7 oocytes, which is
far above the adopted POR threshold (4, 46), might still denote
an inappropriate ovarian response to stimulation. Nevertheless,
very few trials have investigated the role of interventions in
women with ovarian resistance (i.e., hypo-responsiveness) to OS
and until recently no practical guidelines were available.
An increase in the daily dose of exogenous FSH represents the
intuitive approach to overcome ovarian resistance to exogenous
FSH, and it was indeed adopted by several investigators. This
strategy might be applied to rescue an ongoing OS cycle in
women with an initial slow (“steady”) response to gonadotropin
stimulation (7, 8, 47). Increased FSH dosages has been mostly
utilized in women treated with GnRH-a long protocols, where
follicle “stagnation” during the first days of OS is more frequently
detected. The increase in the FSH starting dose might be also
an option in women who show hypo-sensitivity to gonadotropin
stimulation in a previous cycle. In the latter, use of higher
dosages of recombinant FSH might mitigate the negative effect
of FSHR polymorphisms on ovarian response. In one study,
Behre et al. demonstrated that increasing the daily FSH dose
might counteract the negative effect of FSHR polymorphisms
in normogonadotropic women with p.N680SA > G, rs6166
haplotype. In their study, the recombinant FSH dose of 225
IU/day was able to prevent low estradiol levels achieved at the
end of OS in p.N680SA>G G homozygous stimulated with
150 IU/day (16). These results were corroborated by a 2012
study conducted by Genro et al. The authors reported that the
FORT was not significantly influenced by the presence of FSHR
p.N680SA > G, rs6166 polymorphism when a high FSH dose
(300 IU per day) was given during OS (48).
Based on the aforementioned observations, one could
argue that a starting FSH dose between 225–300 IU should
be considered for all good prognosis patients undergoing
ART, independently of genotype characterization. Although
this approach might counteract the vast majority of the
polymorphisms of gonadotrophins and their receptors, it is
clearly not cost-effective. The study by Behre et al. (16)
mentioned above indicates that a remarkable proportion of
untested women would achieve an optimal FORT with a lower
FSH starting dose. In addition, the MERIT study demonstrated
that the indiscriminate use of a 225 IU/day FSH starting dose led
to progesterone rise in a relevant percentage of women with good
ovarian reserve (49). In this study, progesterone elevation was
not observed if a starting dose of 150 IU/day had been adopted
(50). Hence, FSHR genotype testing before OS might be clinically
useful and cost-effective to identify those women who benefit
from an increment in the FSH starting dose from those who do
not (28).
The use of recombinant LH (r-hLH) supplementation has also
been investigated as a means to overcome hypo-responsiveness
to gonadotropin stimulation (51–53). Recently, a systematic
review compiled the evidence concerning the use of r-hLH
supplementation in hypo-responder women undergoing IVF
(15). From the analysis of RCTs, the authors concluded that
addition of rLH might be more advantageous than increasing
rFSH dosage. Notwithstanding the promising results with the use
of r-LH in hypo-responders, the existing literature is limited by
the availability of only few reports, thus indicating the need of
further research. Likewise, the use antioxidant supplementation
as a means of alleviating the plausible negative effects of
ROS on the follicular environment and ovarian resistance to
gonadotropin stimulation is open for research.
CONCLUSION
Several non-mutually exclusive factors seem to influence ovarian
resistance to gonadotropin stimulation. The driving theory
explaining its pathophysiology relies on the genotypic profile
of gonadotropins and their receptors. Genetic phenotyping of
relevant polymorphisms seems to be the optimal method to
identify these patients. Until genotyping testing becomes widely
available, other indices such as the FORT and FOI can be used
as surrogate measures to identify women with ovarian resistance
(hypo-responsiveness) to gonadotropin stimulation. Particularly,
FOI, assessing the actual number of oocytes retrieved could
represent a better tool to determine whether the ovarian reserve
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was adequately exploited during stimulation. Guidance on how
to most optimally manage patients with hypo-response to
OS is lacking, but limited evidence indicates that the use of
higher FSH daily doses alone or combined with recombinant
LH supplementation are the most effective ways to counteract
the negative effects of hypo-responsiveness to exogenous
gonadotropin administration. Further research is warranted to
fully unravel the underlying mechanisms leading to ovarian
resistance to gonadotropin stimulation and to determine the
most prevalent polymorphisms associated with this condition.
Additionally, the impact of different pharmacological regimens
as a means of overcoming ovarian resistance to gonadotropin
stimulation needs to be investigated in more detail.
AUTHOR CONTRIBUTIONS
CA, AC, SE, CYA, and GD idealized the paper and wrote the first
draft. RVa, RVe, SS, and EC participated in literature research
and paper writing. All author listed have made intellectual
contribution to the work and approved the final version.
REFERENCES
1. Sunkara SK, Rittenberg V, Raine-Fenning N, Bhattacharya S, Zamora J,
Coomarasamy A. Association between the number of eggs and
live birth in IVF treatment: an analysis of 400 135 treatment
cycles. Hum Reprod. (2011) 26:1768–74. doi: 10.1093/humrep/
der106
2. Conforti A, Cariati F, Vallone R, Alviggi C, de Placido G. Individualization
of treatment in controlled ovarian stimulation: myth or reality? Biochim Clin.
(2017) 41:294–305. doi: 10.19186/BC_2017.051
3. La Marca A, Sunkara SK. Individualization of controlled ovarian
stimulation in IVF using ovarian reserve markers: from theory to
practice. Hum Reprod Update (2014) 20:124–40. doi: 10.1093/humupd/
dmt037
4. Alviggi C, Andersen CY, Buehler K, Conforti A, De PlacidoG, Esteves SC, et al.
A new more detailed stratification of low responders to ovarian stimulation:
from a poor ovarian response to a low prognosis concept. Fertil Steril. (2016)
105:1452–3. doi: 10.1016/j.fertnstert.2016.02.005
5. Devroey P, Fauser BC, Diedrich K. Approaches to improve the diagnosis
and management of infertility. Hum Reprod Update (2009) 15:391–408.
doi: 10.1093/humupd/dmp012
6. Esteves SC, Humaidan P, Alviggi C, Fischer R. The novel POSEIDON
stratification of ’Low prognosis patients in Assisted Reproductive Technology’
and its proposed marker of successful outcome. F1000Res. (2016) 5:2911.
doi: 10.12688/f1000research.10382.1
7. De Placido G, Alviggi C, Perino A, Strina I, Lisi F, Fasolino A, et al.
Recombinant human LH supplementation versus recombinant human
FSH (rFSH) step-up protocol during controlled ovarian stimulation in
normogonadotrophic women with initial inadequate ovarian response to
rFSH. A multicentre, prospective, randomized controlled trial. Hum Reprod.
(2005) 20:390–6. doi: 10.1093/humrep/deh625
8. Ferraretti AP, Gianaroli L, Magli MC, D’Angelo A, Farfalli V, Montanaro N.
Exogenous luteinizing hormone in controlled ovarian hyperstimulation
for assisted reproduction techniques. Fertil Steril. (2004) 82:1521–6.
doi: 10.1016/j.fertnstert.2004.06.041
9. Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC.
Lower apoptosis rate in human cumulus cells after administration
of recombinant luteinizing hormone to women undergoing ovarian
stimulation for in vitro fertilization procedures. Fertil Steril. (2007) 87:542–6.
doi: 10.1016/j.fertnstert.2006.06.059
10. Drakopoulos P, Blockeel C, Stoop D, Camus M, de Vos M, Tournaye H, et al.
Conventional ovarian stimulation and single embryo transfer for IVF/ICSI.
How many oocytes do we need to maximize cumulative live birth rates after
utilization of all fresh and frozen embryos? Hum Reprod. (2016) 31:370–6.
doi: 10.1093/humrep/dev316
11. Genro VK, Grynberg M, Scheffer JB, Roux I, Frydman R, Fanchin R.
Serum anti-Mullerian hormone levels are negatively related to
Follicular Output RaTe (FORT) in normo-cycling women undergoing
controlled ovarian hyperstimulation. Hum Reprod. (2011) 26:671–7.
doi: 10.1093/humrep/deq361
12. Gallot V, Berwanger da Silva AL, Genro V, Grynberg M, Frydman N,
Fanchin R. Antral follicle responsiveness to follicle-stimulating hormone
administration assessed by the Follicular Output RaTe (FORT) may predict in
vitro fertilization-embryo transfer outcome. Hum Reprod. (2012) 27:1066–72.
doi: 10.1093/humrep/der479
13. Biasoni V, Patriarca A, Dalmasso P, Bertagna A, Manieri C, Benedetto C, et al.
Ovarian sensitivity index is strongly related to circulating AMH and may be
used to predict ovarian response to exogenous gonadotropins in IVF. Reprod
Biol Endocrinol. (2011) 9:112. doi: 10.1186/1477-7827-9-112
14. Esteves SC, Alviggi C. The role of LH in controlled ovarian stimulation.
In: Ghumman S, editor. Principles and Practice of Controlled Ovarian
Stimulation in Art. New Delhi: Springer India (2015). p. 171–96.
doi: 10.1007/978-81-322-1686-5_16
15. Alviggi C, Conforti A, Esteves SC, Andersen CY, Bosch E, Buhler K,
et al. Recombinant luteinizing hormone supplementation in assisted
reproductive technology: a systematic review. Fertil Steril. (2018) 109:644–64.
doi: 10.1016/j.fertnstert.2018.01.003
16. Behre HM, Greb RR, Mempel A, Sonntag B, Kiesel L, Kaltwasser P,
et al. Significance of a common single nucleotide polymorphism in
exon 10 of the follicle-stimulating hormone (FSH) receptor gene for
the ovarian response to FSH: a pharmacogenetic approach to controlled
ovarian hyperstimulation. Pharmacogenet Genomics (2005) 15:451–6.
doi: 10.1097/01.fpc.0000167330.92786.5e
17. Conway GS, Conway E, Walker C, Hoppner W, Gromoll J, Simoni M.
Mutation screening and isoform prevalence of the follicle stimulating
hormone receptor gene in women with premature ovarian failure, resistant
ovary syndrome and polycystic ovary syndrome. Clin Endocrinol. (1999)
51:97–9. doi: 10.1046/j.1365-2265.1999.00745.x
18. Greb RR, Grieshaber K, Gromoll J, Sonntag B, Nieschlag E, Kiesel L, et al. A
common single nucleotide polymorphism in exon 10 of the human follicle
stimulating hormone receptor is a major determinant of length and hormonal
dynamics of the menstrual cycle. J Clin Endocrinol Metab. (2005) 90:4866–72.
doi: 10.1210/jc.2004-2268
19. Gromoll J, Simoni M. Genetic complexity of FSH receptor function. Trends
Endocrinol Metab. (2005) 16:368–73. doi: 10.1016/j.tem.2005.05.011
20. Perez Mayorga M, Gromoll J, Behre HM, Gassner C, Nieschlag E, Simoni M.
Ovarian response to follicle-stimulating hormone (FSH) stimulation depends
on the FSH receptor genotype. J Clin Endocrinol Metab. (2000) 85:3365–9.
doi: 10.1210/jcem.85.9.6789
21. Levallet J, Pakarinen P, Huhtaniemi IT. Follicle-stimulating hormone ligand
and receptor mutations, and gonadal dysfunction. Arch Med Res. (1999)
30:486–94. doi: 10.1016/s0188-0128(99)00058-5
22. Themmen APN, Huhtaniemi IT. Mutations of gonadotropins and
gonadotropin receptors: elucidating the physiology and pathophysiology
of pituitary-gonadal function. Endocr Rev. (2000) 21:551–83.
doi: 10.1210/edrv.21.5.0409
23. Conforti A, Alfano S, De Rosa P, Alviggi C, De Placido G. The role of
gonadotropin polymorphisms and their receptors in assisted reproductive
technologies and controlled ovarian stimulation: a prospective observational
study. Ital J Gynaecol Obstetr. (2017) 29:15–21. doi: 10.14660/2385-0868-67
24. La Marca A, Papaleo E, Alviggi C, Ruvolo G, De Placido G, Candiani M,
et al. The combination of genetic variants of the FSHB and FSHR genes affects
serum FSH in women of reproductive age. Hum Reprod. (2013) 28:1369–74.
doi: 10.1093/humrep/det061
25. Alviggi C, Conforti A, Esteves SC. Impact of mutations and polymorphisms
of gonadotrophins and their receptors on the outcome of controlled
Frontiers in Endocrinology | www.frontiersin.org 6 October 2018 | Volume 9 | Article 589
Alviggi et al. Hypo-Response to Exogenous Gonadotropin
ovarian stimulation. In: Ghumman S, editor. Principles and Practice of
Controlled Ovarian Stimulation in ART. New Delhi (2015). p. 147–56.
doi: 10.1007/978-81-322-1686-5_14
26. Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, et al.
Suboptimal response to GnRHa long protocol is associated with a common
LH polymorphism. Reprod Biomed Online (2011) 22 (Suppl 1):S67–72.
doi: 10.1016/s1472-6483(11)60011-4
27. Alviggi C, Conforti A, Fabozzi F, De Placido G. Ovarian stimulation for
IVF/ICSI cycles: a pharmacogenomic approach. Med Therapeut Med Reprod
Gynecol Endocrinol. (2009) 11:271–7. doi: 10.1684/mte.2009.0255
28. Alviggi C, Conforti A, Santi D, Esteves SC, Andersen CY, Humaidan P, et al.
Clinical relevance of genetic variants of gonadotrophins and their receptors in
controlled ovarian stimulation: a systematic review and meta-analysis. Hum
Reprod Update (2018) 24:599–614. doi: 10.1093/humupd/dmy019
29. Alviggi C, Pettersson K, Longobardi S, Andersen CY, Conforti A, De
Rosa P, et al. A common polymorphic allele of the LH beta-subunit gene
is associated with higher exogenous FSH consumption during controlled
ovarian stimulation for assisted reproductive technology. Reprod Biol
Endocrinol. (2013) 11:51. doi: 10.1186/1477-7827-11-51
30. Alviggi C, Conforti A, Caprio F, Gizzo S, Noventa M, Strina I, et al.
In estimated good prognosis patients could unexpected “hyporesponse”
to controlled ovarian stimulation be related to genetic polymorphisms
of FSH receptor? Reprod Sci. (2016) 23:1103–8. doi: 10.1177/1933719116
630419
31. Casarini L, Moriondo V, Marino M, Adversi F, Capodanno F, Grisolia C, et al.
FSHR polymorphism p.N680S mediates different responses to FSH in vitro.
Mol Cell Endocrinol. (2014) 393:83–91. doi: 10.1016/j.mce.2014.06.013
32. Casarini L, Santi D, Marino M. Impact of gene polymorphisms of
gonadotropins and their receptors on human reproductive success.
Reproduction (2015) 150:R175–84. doi: 10.1530/rep-15-0251
33. Mohiyiddeen L, Nardo LG. Single-nucleotide polymorphisms in the FSH
receptor gene and ovarian performance: future role in IVF.Hum Fertil. (2010)
13:72–8. doi: 10.3109/14647271003632322
34. Achrekar SK, Modi DN, Desai SK, Mangoli VS, Mangoli RV, Mahale SD.
Poor ovarian response to gonadotrophin stimulation is associated with
FSH receptor polymorphism. Reprod Biomed Online (2009) 18:509–15.
doi: 10.1016/s1472-6483(10)60127-7
35. Desai SS, Achrekar SK, Pathak BR, Desai SK, Mangoli VS, Mangoli RV, et al.
Follicle-stimulating hormone receptor polymorphism (G-29A) is associated
with altered level of receptor expression in Granulosa cells. J Clin Endocrinol
Metab. (2011) 96:2805–12. doi: 10.1210/jc.2011-1064
36. Alviggi C, Guadagni R, Conforti A, Coppola G, Picarelli S, De Rosa P, et al.
Association between intrafollicular concentration of benzene and outcome of
controlled ovarian stimulation in IVF/ICSI cycles: a pilot study. J Ovarian Res.
(2014) 7:67. doi: 10.1186/1757-2215-7-67
37. Mahalingaiah S, Missmer SA, Maity A,Williams PL, Meeker JD, Berry K, et al.
Association of hexachlorobenzene (HCB), dichlorodiphenyltrichloroethane
(DDT), and dichlorodiphenyldichloroethylene (DDE) with in vitro
fertilization (IVF) outcomes. Environ Health Perspect. (2012) 120:316–20.
doi: 10.1289/ehp.1103696
38. Bloom MS, Fujimoto VY, Storm R, Zhang L, Butts CD, Sollohub D, et al.
Persistent organic pollutants (POPs) in human follicular fluid and in vitro
fertilization outcomes, a pilot study. Reprod Toxicol. (2017) 67:165–73.
doi: 10.1016/j.reprotox.2017.01.004
39. Agarwal A, Gupta S, Sharma R. Oxidative stress and its implications in female
infertility - a clinician’s perspective. Reprod Biomed Online (2005) 11:641–50.
doi: 10.1016/s1472-6483(10)61174-1
40. Velthut A, Zilmer M, Zilmer K, Kaart T, Karro H, Salumets A. Elevated blood
plasma antioxidant status is favourable for achieving IVF/ICSI pregnancy.
Reprod Biomed Online (2013) 26:345–52. doi: 10.1016/j.rbmo.2012.
12.012
41. Agarwal A, Saleh RA, Bedaiwy MA. Role of reactive oxygen species in
the pathophysiology of human reproduction. Fertil Steril. (2003) 79:829–43.
doi: 10.1016/S0015-0282(02)04948-8
42. Showell MG, Mackenzie-Proctor R, Jordan V, Hart RJ. Antioxidants
for female subfertility. Cochrane Database Syst Rev. (2017) 7:Cd007807.
doi: 10.1002/14651858.CD007807.pub3
43. Alviggi C, Conforti A, Rosa PD, Strina I, Palomba S, Vallone R, et al.
The distribution of stroma and antral follicles differs between insulin-
resistance and hyperandrogenism related polycystic ovarian syndrome. Front
Endocrinol. (2017) 8:117. doi: 10.3389/fendo.2017.00117
44. Alviggi C, Cariati F, Conforti A, De Rosa P, Vallone R, Strina I, et al. The effect
of FT500 Plus((R)) on ovarian stimulation in PCOS women. Reprod Toxicol.
(2016) 59:40–4. doi: 10.1016/j.reprotox.2015.10.014
45. Xu Y, Nisenblat V, Lu C, Li R, Qiao J, Zhen X, et al. Pretreatment
with coenzyme Q10 improves ovarian response and embryo quality
in low-prognosis young women with decreased ovarian reserve: a
randomized controlled trial. Reprod Biol Endocrinol. (2018) 16:29.
doi: 10.1186/s12958-018-0343-0
46. Ferraretti AP, La Marca A, Fauser BC, Tarlatzis B, Nargund G, Gianaroli L.
ESHRE consensus on the definition of ’poor response’ to ovarian stimulation
for in vitro fertilization: the Bologna criteria.Hum Reprod. (2011) 26:1616–24.
doi: 10.1093/humrep/der092
47. De Placido G, Mollo A, Alviggi C, Strina I, Varricchio MT, Ranieri A,
et al. Rescue of IVF cycles by HMG in pituitary down-regulated
normogonadotrophic young women characterized by a poor initial
response to recombinant FSH. Hum Reprod. (2001) 16:1875–9.
doi: 10.1093/humrep/16.9.1875
48. Genro VK, Matte U, De Conto E, Cunha-Filho JS, Fanchin R. Frequent
polymorphisms of FSH receptor do not influence antral follicle responsiveness
to follicle-stimulating hormone administration as assessed by the
Follicular Output RaTe (FORT). J Assist Reprod Genet. (2012) 29:657–63.
doi: 10.1007/s10815-012-9761-7
49. Andersen AN, Devroey P, Arce JC. Clinical outcome following stimulation
with highly purified hMG or recombinant FSH in patients undergoing IVF: a
randomized assessor-blind controlled trial. Hum Reprod. (2006) 21:3217–27.
doi: 10.1093/humrep/del284
50. Devroey P, Pellicer A, Nyboe Andersen A, Arce J-C. A randomized assessor-
blind trial comparing highly purified hMG and recombinant FSH in a GnRH
antagonist cycle with compulsory single-blastocyst transfer. Fertil Steril.
(2012) 97:561–71. doi: 10.1016/j.fertnstert.2011.12.016
51. Alviggi C, Mollo A, Clarizia R, De Placido G. Exploiting LH
in ovarian stimulation. Reprod Biomed Online (2006) 12:221–33.
doi: 10.1016/S1472-6483(10)60865-6
52. Alviggi C, Clarizia R, Mollo A, Ranieri A, De Placido G. Who needs LH
in ovarian stimulation? Reprod Biomed Online (2011) 22 (Suppl. 1):S33–41.
doi: 10.1016/S1472-6483(11)60007-2
53. Santi D, Casarini L, Alviggi C, Simoni M. Efficacy of follicle-stimulating
hormone (FSH) alone, FSH + luteinizing hormone, human menopausal
gonadotropin or FSH + human chorionic gonadotropin on assisted
reproductive technology outcomes in the “personalized” medicine era: a
meta-analysis. Front Endocrinol. (2017) 8:114. doi: 10.3389/fendo.2017.00114
Conflict of Interest Statement: CA, AC, SE, CYA, and GD are Poseidon members.
The remaining authors declare that the research was conducted in the absence of
any commercial or financial relationships that could be construed as a potential
conflict of interest.
The reviewer GB declared a past co-authorship with several of the authors
SE, CA, and AC to the handling editor.
Copyright © 2018 Alviggi, Conforti, Esteves, Vallone, Venturella, Staiano, Castaldo,
Andersen and De Placido. This is an open-access article distributed under the terms
of the Creative Commons Attribution License (CC BY). The use, distribution or
reproduction in other forums is permitted, provided the original author(s) and the
copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.
Frontiers in Endocrinology | www.frontiersin.org 7 October 2018 | Volume 9 | Article 589
